On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

Alzheimer's Association of Israel

InstitutionResearch output, impact & collaborations

Alzheimer's Association of Israel is a institution indexed in ScholarIQ from OpenAlex.

What is known about Alzheimer's Association of Israel?

ScholarIQrecord summary

Alzheimer's Association of Israel is a research organisation in Ramat Gan, IL. OpenAlex records 1,251 works and 57,691 citations for it. 505 researchers list it as their most recent affiliation.

How many works does Alzheimer's Association of Israel have?

ScholarIQindexed works

Alzheimer's Association of Israel has 1,251 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Alzheimer's Association of Israel →

How many citations does Alzheimer's Association of Israel have?

ScholarIQcitation count

Alzheimer's Association of Israel has 57,691 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Alzheimer's Association of Israel →

How many researchers are at Alzheimer's Association of Israel?

ScholarIQresearcher count

Alzheimer's Association of Israel has 505 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Alzheimer's Association of Israel?

ScholarIQavg h-index

Alzheimer's Association of Israel has an average h-index of 56 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Alzheimer's Association of Israel?

ScholarIQror

The ROR for Alzheimer's Association of Israel is on the source record.

Open the ROR →

What is the OpenAlex record for Alzheimer's Association of Israel?

ScholarIQopenalex

The OpenAlex for Alzheimer's Association of Israel is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Alzheimer's Association of Israel?

ScholarIQtop researchers by citations

Ofri Mosenzon · Diabetes Treatment and Management

268 works27,236 citations

What are the most-cited papers on Alzheimer's Association of Israel?

ScholarIQmost cited works

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca, Ofri Mosenzon, Eri Kato, Avivit Cahn, Michael G. Silverman, Thomas A. Zelniker, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Christian T. Ruff, Ingrid Gause‐Nilsson, Martin Fredriksson, Peter A. Johansson, Anna-Maria Langkilde, Marc S. Sabatine

New England Journal of Medicine. 20186,387 CitationsOPEN ACCESS

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald, Philippe Gabríel Steg, Jaime A. Davidson, Boaz Hirshberg, Peter Öhman, Robert Frederich, Stephen D. Wiviott, Elaine Hoffman, Matthew A. Cavender, Jacob A. Udell, Nihar R. Desai, Ofri Mosenzon, Darren K. McGuire, Kausik K. Ray, Lawrence A. Leiter, Itamar Raz

New England Journal of Medicine. 20133,486 CitationsOPEN ACCESS

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Thomas A. Zelniker, Stephen D. Wiviott, Itamar Raz, KyungAh Im, Erica L. Goodrich, Marc P. Bonaca, Ofri Mosenzon, Eri Kato, Avivit Cahn, Remo H.M. Furtado, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Marc S. Sabatine

The Lancet. 20182,848 Citations

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G. Eliaschewitz, Denise Reis Franco, Ole Kleist Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D. Pedersen, Cees J. Tack, Mette S. Thomsen, Tina Vilsbøll, Mark Warren, Stephen C. Bain

New England Journal of Medicine. 20191,969 CitationsOPEN ACCESS

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

Patrick M. O’Neil, Andreas L. Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D. Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie H. Jepsen, Maria Kabisch, John Wilding

The Lancet. 2018813 Citations

How much of the research on Alzheimer's Association of Israel is open access?

ScholarIQopen access share

58%OPEN ACCESS

Gold

Green

Hybrid

Bronze

58%

Closed

42%